Malaria vaccines: a toy for travelers or a tool for eradication? (Q37194780)

18 August 2017

1 reference

title

Malaria vaccines: a toy for travelers or a tool for eradication? (English)

1 reference

eradication of infectious diseases

18 August 2017

0 references

1 reference

1 reference

1

Blaise Genton

1 reference

18 August 2017

publication date

1 July 2008

1 reference

Expert Review of Vaccines

18 August 2017

published in

1 reference

18 August 2017

volume

7

1 reference

18 August 2017

issue

5

1 reference

18 August 2017

page(s)

597-611

1 reference

Malaria eradication back on the table

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Effectiveness of malaria control during changing climate conditions in Eritrea, 1998-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

The decline in paediatric malaria admissions on the coast of Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Malaria in travelers: a review of the GeoSentinel surveillance network.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Risk of malaria in British residents returning from malarious areas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Malaria risk in travelers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Malaria prophylaxis policy for travellers from Europe to the Indian Subcontinent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

The low and declining risk of malaria in travellers to Latin America: is there still an indication for chemoprophylaxis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Genome sequence of the human malaria parasite Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Genome-wide variation and identification of vaccine targets in the Plasmodium falciparum genome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

New concepts in vaccine development in malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Identification of humoral immune responses in protein microarrays using DNA microarray data analysis techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Protein structure based strategies for antigen discovery and vaccine development against malaria and other pathogens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

A systematic map of genetic variation in Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Molecular monitoring in malaria vaccine trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

A review of human vaccine research and development: malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Baculovirus as an expression and/or delivery vehicle for vaccine antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Peptide based malaria vaccine development: personal considerations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Functional and immunological insights from the three-dimensional structures of Plasmodium surface proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Malaria vaccines: the stage we are at.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Optimized Malaria-antigens delivered by immunostimulating reconstituted influenza virosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-ba

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Plasmodium falciparum malaria vaccines in development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Pre-erythrocytic stage malaria vaccines: time for a change in path

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

21 January 2018

RTS,S/AS02A for malaria

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

The immunological challenges of malaria vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N- and C-terminal regions of the Plasmodium falciparum CS protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Synthetic polypeptides corresponding to the non-repeat regions from the circumsporozoite protein of Plasmodium falciparum: recognition by human T-cells and immunogenicity in owl monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

OM-174, a new adjuvant with a potential for human use, induces a protective response when administered with the synthetic C-terminal fragment 242–310 from the circumsporozoite protein of Plasmodium berghei

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Pre-erythrocytic antigens of Plasmodium falciparum: from rags to riches?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Process development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Immunogenicity and protective efficacy of Plasmodium falciparum liver‐stage Ag‐3 in Aotus lemurinus griseimembra monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Malaria vaccine development: progress and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Selection of glutamate-rich protein long synthetic peptides for vaccine development: antigenicity and relationship with clinical protection and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Characterization of proteases involved in the processing of Plasmodium falciparum serine repeat antigen (SERA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

A systematic approach to stabilizing EBA-175 RII-NG for use as a malaria vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Immunization of Aotus monkeys with recombinant cysteine-rich interdomain region 1 alpha protects against severe disease during Plasmodium falciparum reinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Vaccine development against malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Mass spectrometric analysis of Plasmodium falciparum erythrocyte membrane protein-1 variants expressed by placental malaria parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Evidence for the involvement of VAR2CSA in pregnancy-associated malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Characterization of anti-var2CSA-PfEMP1 cytoadhesion inhibitory mouse monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Epitope mapping and topographic analysis of VAR2CSA DBL3X involved in P. falciparum placental sequestration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Vaccines against malaria - an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuatedPlasmodium falciparumsporozoite vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Genetically attenuated Plasmodium berghei liver stages induce sterile protracted protection that is mediated by major histocompatibility complex Class I-dependent interferon-gamma-producing CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Prevention of malaria in long-term travelers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Do travelers really take their mefloquine malaria chemoprophylaxis? Estimation of adherence by an electronic pillbox

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.597

21 January 2018

Identifiers

DOI

10.1586/14760584.7.5.597

1 reference

release_ifqkfip5nrgkbpxabnl3lqxixm

18 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ifqkfip5nrgkbpxabnl3lqxixm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference